{"id":"continuous-subcutaneous-lisuride-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1257128","moleculeType":"Small molecule","molecularWeight":"454.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lisuride acts as a non-ergot dopamine agonist, binding to D2 and D1 dopamine receptors in the brain. By stimulating these receptors, it compensates for the loss of dopamine-producing neurons characteristic of Parkinson's disease, thereby reducing motor fluctuations and dyskinesias. Continuous subcutaneous infusion allows for steady-state dopamine receptor stimulation, potentially reducing the on-off motor fluctuations associated with oral or intermittent dosing.","oneSentence":"Lisuride is a dopamine agonist that activates dopamine receptors to improve motor symptoms and reduce involuntary movements in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:31.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease with motor fluctuations and dyskinesias"}]},"trialDetails":[{"nctId":"NCT00408915","phase":"PHASE3","title":"Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion","status":"COMPLETED","sponsor":"Axxonis Pharma AG","startDate":"2006-07","conditions":"Parkinson's Disease","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous Subcutaneous Lisuride Infusion","genericName":"Continuous Subcutaneous Lisuride Infusion","companyName":"Axxonis Pharma AG","companyId":"axxonis-pharma-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous Subcutaneous Lisuride Infusion is a treatment for Parkinson's Disease. It involves the continuous subcutaneous infusion of lisuride, a medication that has been studied in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}